TY  - JOUR
AU  - Gil-Bernal, Rosalía
AU  - González-Caballero, Juan Luis
AU  - Espinosa-Rosso, Raúl
AU  - Gómez-Gómez, Carmen
PY  - 2021
DO  - 10.1038/s41598-021-91912-x
UR  - http://hdl.handle.net/10668/18001
T2  - Scientific reports
AB  - Neoplasm development in Multiple Sclerosis (MS) patients treated with disease-modifying therapies (DMTs) has been widely discussed. The aim of this work is to determine neoplasm frequency, relationship with the prescription pattern of DMTs, and...
LA  - en
KW  - Adult
KW  - Aged
KW  - Alemtuzumab
KW  - Crotonates
KW  - Dimethyl Fumarate
KW  - Female
KW  - Fingolimod Hydrochloride
KW  - Glatiramer Acetate
KW  - Humans
KW  - Hydroxybutyrates
KW  - Immunosuppressive Agents
KW  - Interferon-beta
KW  - Male
KW  - Middle Aged
KW  - Multiple Sclerosis
KW  - Multiple Sclerosis, Chronic Progressive
KW  - Multiple Sclerosis, Relapsing-Remitting
KW  - Natalizumab
KW  - Neoplasms
KW  - Nitriles
KW  - Outpatients
KW  - Proportional Hazards Models
KW  - Risk Factors
KW  - Smoking
KW  - Spain
KW  - Toluidines
TI  - Potential risk of disease modifying therapies on neoplasm development and coadjutant factors in multiple sclerosis outpatients.
TY  - research article
VL  - 11
ER  -